Related Experiment Videos
Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study.
S Oksa1, T Luukkaala, J Mäenpää
1Department of Obstetrics and Gynaecology, Satakunta Central Hospital, Pori, Finland. sinikka.oksa@satshp.fi
Summary
Toremifene effectively reduced premenstrual mastalgia pain scores by 64% compared to placebo's 26% reduction. This antiestrogenic treatment offers significant breast pain relief without major adverse effects.
Area of Science:
- Endocrinology
- Pharmacology
- Women's Health
Background:
- Premenstrual mastalgia significantly impacts women's quality of life.
- Effective and safe treatment options are needed for cyclic breast pain.
Purpose of the Study:
- To evaluate the efficacy of toremifene in alleviating premenstrual mastalgia.
- To assess the impact of toremifene on quality of life in affected women.
Main Methods:
- A double-blind, placebo-controlled crossover study involving 62 women aged 25-45 with premenstrual mastalgia.
- Participants received toremifene (20 mg daily) or placebo for three cycles, followed by a crossover period.
- Pain relief was measured using the visual analogue scale (VAS), and quality of life was assessed using a modified Finnish Depression Scale.
Main Results:
- Toremifene treatment resulted in a significantly greater reduction in VAS pain scores (64%) compared to placebo (26%).
- Median VAS scores were 1.8 for toremifene and 3.7 for placebo (P=0.004).
- Quality of life scores were comparable between toremifene and placebo treatment cycles.
Conclusions:
- Toremifene, an antiestrogenic compound, demonstrates significant efficacy in relieving premenstrual mastalgia.
- The treatment is well-tolerated, with no major adverse effects reported.
- Toremifene offers a promising therapeutic option for managing cyclic breast pain.